AU3831300A - Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them - Google Patents

Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them Download PDF

Info

Publication number
AU3831300A
AU3831300A AU38313/00A AU3831300A AU3831300A AU 3831300 A AU3831300 A AU 3831300A AU 38313/00 A AU38313/00 A AU 38313/00A AU 3831300 A AU3831300 A AU 3831300A AU 3831300 A AU3831300 A AU 3831300A
Authority
AU
Australia
Prior art keywords
phenoxazin
ethoxy
phenyl
ethoxypropanoic acid
arginine salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU38313/00A
Other languages
English (en)
Inventor
Sreenivasa Rao Dharmaraja
Om Reddy Gaddam
Vyas Krishnamurthi
Ramabhadra Sarma Mamillapalli
Rajender Kumar Potlapally
Raju Sirisilla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/fr
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of AU3831300A publication Critical patent/AU3831300A/en
Assigned to DR. REDDY'S LABORATORIES LIMITED reassignment DR. REDDY'S LABORATORIES LIMITED Alteration of Name(s) of Applicant(s) under S113 Assignors: DR. REDDY'S RESEARCH FOUNDATION
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU38313/00A 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them Abandoned AU3831300A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IB1999/000681 WO2000063191A1 (fr) 1999-04-16 1999-04-16 Nouvelles formes polymorphes d'un agent antidiabetique: procede de preparation et composition pharmaceutique contenant ces dernieres
WO900681 1999-04-16
IN436/MAS/99 1999-04-19
IN436MA1999 1999-04-19
PCT/IB2000/000470 WO2000063192A1 (fr) 1999-04-16 2000-04-17 Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
AU3831300A true AU3831300A (en) 2000-11-02

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38313/00A Abandoned AU3831300A (en) 1999-04-16 2000-04-17 Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them

Country Status (17)

Country Link
EP (1) EP1171430A1 (fr)
CN (1) CN1351597A (fr)
AU (1) AU3831300A (fr)
BG (1) BG106022A (fr)
BR (1) BR0010683A (fr)
CA (1) CA2370401A1 (fr)
CZ (1) CZ20013711A3 (fr)
EE (1) EE200100529A (fr)
HR (1) HRP20010748A2 (fr)
HU (1) HUP0200758A3 (fr)
IL (1) IL145958A0 (fr)
MX (1) MXPA01010472A (fr)
NO (1) NO20015016L (fr)
PL (1) PL351492A1 (fr)
RU (1) RU2001130883A (fr)
TR (1) TR200103851T2 (fr)
WO (1) WO2000063192A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309818T1 (de) 2000-03-08 2005-12-15 Novo Nordisk As Senkung des serum cholesterols
US6897199B2 (en) * 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
WO2003031432A1 (fr) 2001-10-12 2003-04-17 Novo Nordisk A/S Nouvelles piperidines substituees
US20030171411A1 (en) 2001-12-21 2003-09-11 Kodra Janos Tibor Amide derivatives as therapeutic agents
JP5142448B2 (ja) * 2002-04-19 2013-02-13 ファエス・ファルマ・ソシエダッド・アノニマ ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
KR101116627B1 (ko) 2002-06-27 2012-10-09 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
WO2004101505A1 (fr) 2003-05-14 2004-11-25 Novo Nordisk A/S Nouveaux composes pour le traitement de l'obesite
WO2005030797A2 (fr) 2003-09-30 2005-04-07 Novo Nordisk A/S Nouveaux agonistes du recepteur de la melanocortine
JP4865565B2 (ja) 2003-12-09 2012-02-01 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニストを用いた食物選択の制御
SI1723128T1 (sl) 2004-01-06 2013-04-30 Transtech Pharma, Inc. Heteroaril uree in njihova uporaba kot aktivatorji glukokinaze
WO2005105785A2 (fr) 2004-05-04 2005-11-10 Novo Nordisk A/S Nouveaux derives d'indole
EP2316446A1 (fr) 2004-06-11 2011-05-04 Novo Nordisk A/S Remède contre l'obésité induite par les médicaments au moyen d'agonistes GLP-1
CN101060856B (zh) 2004-11-22 2011-01-19 诺和诺德公司 可溶、稳定的含胰岛素制剂
CA2590720A1 (fr) 2004-12-03 2006-06-08 Lone Jeppesen Composes heteroaromatiques activants de glucokinase
JP5121707B2 (ja) 2005-07-04 2013-01-16 ハイ ポイント ファーマシューティカルズ，エルエルシー 新規医薬
ES2422383T3 (es) 2005-07-14 2013-09-11 Novo Nordisk As Activadores de urea glucoquinasa
US8106090B2 (en) 2005-07-20 2012-01-31 Eli Lilly And Company 1-amino linked compounds
WO2007123581A1 (fr) 2005-11-17 2007-11-01 Eli Lilly And Company Antagonistes des récepteurs du glucagon, leur préparation et leurs utilisations thérapeutiques
AU2007229492B2 (en) 2006-03-28 2011-11-03 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
SG163547A1 (en) 2006-05-29 2010-08-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
CA2669874A1 (fr) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Nouvelles 2-(2-hydroxyphenyl) benzothiadiazines utilisees pour traiter l'obesite et le diabete
ATE523497T1 (de) 2006-11-15 2011-09-15 High Point Pharmaceuticals Llc Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
AU2008204530B2 (en) 2007-01-11 2013-08-01 Vtv Therapeutics Llc Urea glucokinase activators
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
WO2011104378A1 (fr) 2010-02-26 2011-09-01 Novo Nordisk A/S Peptides de traitement de l'obésité
BR112012024379A2 (pt) 2010-03-26 2017-01-10 Novo Nordisk As "peptídeos glucagon, seu uso, bem como composição farmacêutica"
EP2670368A4 (fr) 2011-02-03 2015-04-15 Pharmedica Ltd Nouveaux films à dissolution orale pour administration d'insuline, pour traitement du diabète
AU2012234276A1 (en) 2011-03-28 2013-08-29 Novo Nordisk A/S Novel glucagon analogues
MX354705B (es) 2011-09-23 2018-03-16 Novo Nordisk As Analogos de glucagon novedosos.
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
MY174727A (en) 2013-04-18 2020-05-11 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
JP2020514365A (ja) 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス メラノコルチン４受容体に結合可能な二環式化合物
WO2019219714A1 (fr) 2018-05-15 2019-11-21 Novo Nordisk A/S Composés capables de se lier au récepteur de la mélanocortine 4
WO2020053414A1 (fr) 2018-09-14 2020-03-19 Novo Nordisk A/S Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
IN182496B (fr) * 1996-02-20 1999-04-17 Reddy Research Foundation
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2746099B1 (fr) * 1996-03-13 1998-04-30 Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique
EP0844997A1 (fr) * 1996-06-19 1998-06-03 Dr. Reddy's Research Foundation Nouvelles formes polymorphes de la troglitazone ayant une activite anti-diabetique augmentee et procede pour leur preparation
WO1999019313A1 (fr) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant
JP2002501909A (ja) * 1998-01-29 2002-01-22 ドクター・レディーズ・リサーチ・ファウンデーション 新規なアルカン酸およびその医薬における使用、並びにその製造方法、およびそれを含有する薬学的組成物
PL341795A1 (en) * 1998-05-27 2001-05-07 Reddy Research Foundation Bicycle compounds, process for obtaining them and pharmacological compositions containing such compounds

Also Published As

Publication number Publication date
BR0010683A (pt) 2003-07-01
TR200103851T2 (tr) 2002-04-22
EE200100529A (et) 2002-12-16
WO2000063192A1 (fr) 2000-10-26
CA2370401A1 (fr) 2000-10-26
MXPA01010472A (es) 2002-05-06
NO20015016D0 (no) 2001-10-15
RU2001130883A (ru) 2004-03-20
HUP0200758A2 (hu) 2002-07-29
IL145958A0 (en) 2002-07-25
EP1171430A1 (fr) 2002-01-16
CN1351597A (zh) 2002-05-29
PL351492A1 (en) 2003-04-22
BG106022A (bg) 2002-04-30
HUP0200758A3 (en) 2003-07-28
CZ20013711A3 (cs) 2002-07-17
NO20015016L (no) 2001-12-11
HRP20010748A2 (en) 2003-02-28

Similar Documents

Publication Publication Date Title
AU3831300A (en) Novel polymorphic forms of an antidiabetic agent: process for their preparation and pharmaceutical compositions containing them
JP2003508348A (ja) 新規多型形態の抗糖尿病薬剤：それらの製造方法およびそれらを含有する医薬組成物
WO2000063193A1 (fr) Nouvelles formes polymorphes d'un agent antidiabetique: leur procede de preparation et composition pharmaceutique contenant lesdites formes
CA2426117A1 (fr) Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe
US6528507B1 (en) Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
US20040068116A1 (en) Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2002028857A1 (fr) Polymorphes de chlorhydrates de pioglitazone et leur utilisation en tant qu'antidiabetiques
US6897199B2 (en) Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
EP1363913A2 (fr) Sels de derives de pyrimidine pour utilisation contre les maladies coronaires vasculaires et l'atherosclerose
US20020169175A1 (en) Pharmaceutically acceptable salts of heterocyclic compounds
EP1623984A1 (fr) Polymorphe I du sel de potassium de 5-[4-[[3-methyle-4-oxo-3,4-dihydroquinazoline-2yl]methoxy]benzyle]thiazolidine-2,4-dione
WO2002030914A1 (fr) Sels de derives de benzothiazine et de benzoxazine et compositions pharmaceutiques a base de ces sels
AU2001291232B8 (en) Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
AU2001291232A1 (en) Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
US20020142993A1 (en) Pharmaceutically acceptable salts of bicyclic compounds
WO2003066612A1 (fr) Nouvelles formes polymorphes d'agents bicycliques antidiabetiques, leur procede de preparation et compositions pharmaceutiques les contenant
WO2003006022A1 (fr) Derives de tetrahydroquinoline et leur utilisation en medecine, procede de preparation associe et compositions pharmaceutiques contenant lesdits composes

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20011026

PC1 Assignment before grant (sect. 113)

Owner name: DR. REDDY'S LABORATORIES LIMITED

Free format text: THE FORMER OWNER WAS: DR. REDDY'S RESEARCH FOUNDATION